Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aegon Ltd. (AEG) vs Boston Scientific Corporation (BSX) Price & Performance

Aegon Ltd.Trade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Aegon Ltd. vs Boston Scientific Corporation — how do they compare? Aegon Ltd. trades at $9.41 (market cap $14.01B), while Boston Scientific Corporation trades at $51.53 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 5.3× Aegon Ltd.'s market cap, and Aegon Ltd. pays a 4.94% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

AEGBSX
Market Cap
$14.01B$74.19B
Sector
FinancialsHealth
52-Week High
$9.53$108.14
52-Week Low
$6.79$42.63
Enterprise Value
$15.16B$86.27B
Dividend Yield
4.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aegon Ltd.

AEG trades at $9.41, down 0.48% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $19.5B in 2024 to $26.9B in 2025 and net income increasing to $977M. Recent strategic moves include relocating to Delaware and simplifying governance while maintaining a dividend payout. Analyst consensus is mixed with 28% buy ratings but 50% hold recommendations.

AEG presents a turnaround story with improving profitability and strategic refocusing on US markets. Key opportunities include continued earnings growth and potential buybacks, while risks involve execution of the US transition and maintaining momentum amid volatile cash flow patterns. The stock offers value with a P/E of 13.5 and P/S of 0.57.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aegon Ltd.

Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.

Read more on AEG

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX